ArsenalBio Secures Major Funding for CAR-T Therapies
Arsenal Biosciences, a leader in cell therapy, has successfully raised $325 million with renowned investors like Regeneron and Bristol Myers Squibb (BMS) on board. This funding round is one of the largest in the biotech industry this year. Despite a challenging investment climate, ArsenalBio's CEO, Ken Drazan, M.D., expresses gratitude and determination to use this capital to advance their promising programs.
Exclusive Access: Unlock Premium, Confidential Insights
Unlock This Exclusive Content—Subscribe Instantly!
Login if you have purchased
